[關(guān)鍵詞]
[摘要]
目的研究替吉奧聯(lián)合紫杉醇對進(jìn)展期胃癌的療效和安全性。方法選擇2013年9月-2015年12月在濮陽市油田總醫(yī)院進(jìn)行診治的進(jìn)展期胃癌患者80例,按隨機(jī)數(shù)字表法分為兩組。觀察組給予替吉奧、順鉑聯(lián)合紫杉醇治療,對照組給予替吉奧和紫杉醇治療。兩組患者均以21 d為1個周期,均接受2個周期的治療。觀察兩組患者的近期療效、遠(yuǎn)期療效和不良反應(yīng)發(fā)生情況。結(jié)果觀察組的有效率為52.50%(21/40),明顯高于對照組的40.00%(16/40),兩組比較差異顯著(P<0.05);兩組的中位無進(jìn)展生存時間、中位總生存時間和1年生存率相比無明顯差異;兩組患者主要的不良反應(yīng)為骨髓抑制及消化道反應(yīng),且多為0~Ⅱ度。觀察組的惡心嘔吐反應(yīng)與對照組相比明顯較輕(P<0.05),其他不良反應(yīng)兩組相比無明顯差異。結(jié)論替吉奧、順鉑聯(lián)合紫杉醇對進(jìn)展期胃癌具有較好的臨床療效,且安全性較高,值得臨床推廣應(yīng)用。
[Key word]
[Abstract]
Objective To explore the clinical effect and safety of S-1 combined with paclitaxel in treatment of advanced gastric cancer. Methods 80 patients with advanced gastric cancer accepted in our hospital from Sep.2013 to Dec.2015 were selected and randomly divided into 2 groups. Patients in observation group were given S-1, cisplatin and paclitaxel, and patients in control group were given S-1 and paclitaxel. Then the short term and long term clinical effect and adverse reactions of 2 groups were compared. Results The total effective rate of observation group was 52.50% (21/40), which was obviously higher than 40.00% (16/40) of control group (P < 0.05). The median progression-free survival, median overall survival and 1 year survival rate of 2 groups had no great differences. The main adverse reaction of 2 groups were bone marrow suppression and gastrointestinal reactions of grade 0~Ⅱ. The grade of nausea and vomiting of observation group was much lighter than control group (P < 0.05). But the other adverse reaction of 2 groups had no differences. Conclusion Using S-1, cisplatin and paclitaxel has good effect in treatment of advanced gastric cancer, which is safety and worthy of clinical applications.
[中圖分類號]
[基金項目]